CMIA法在输血前感染性指标检测中的应用研究.pdfVIP

CMIA法在输血前感染性指标检测中的应用研究

王桂萍

【摘要】目的对化学发光微粒子免疫测定(CMIA)技术定量检测输血前感染性指标

的临床应用进行评价.方法用CMIA技术对22235例患者进行输血前乙肝表面抗

原(HBsAg)、抗丙型肝炎病毒抗体(Anti-HCV)、抗梅毒螺旋体特异性抗体(Anti-TP)

及抗人类免疫缺陷病毒抗体(Anti-HIV)定量检测,所有阳性标本用相应的酶联免疫

吸附法(ELISA)进行定性检测,Anti-TP阳性标本用梅毒螺旋体抗体明胶颗粒凝集试

验(TPPA)进行确诊,Anti-HIV阳性标本送市疾控中心进行抗体确认,并对几种方法

的检测结果进行分析.结果HBsAg、Anti-HCV、Anti-TP、Anti-HIV定量检测阳

性例数分别为3028、336、684、63；定量阳性标本经ELISA检测,定性阳性例数

分别为2472,269,668,58；684例Anti-TP定量阳性样本中,用TPPA确认,阳性

603例；63例Anti-HIV定量阳性样本送南充市疾控中心进行确认,48例确定为阳

性,5例不确定,10例为阴性.结论CMIA法定量检测输血前感染性指标可及早发现

感染“窗口期”患者,降低漏检率,有利于患者的早期诊断和治疗,有利于医护人员自

我防护及减少医疗纠纷.%ObjectiveToevaluatetheapplicationof

chemiluminescentmicroparticleimmunoassay(CMIA)technologyin

quantitativedetectionofpre-transfusioninfectionindicators.MethodsThe

pre-transfusionserumlevelsofhepatitisBsurfaceantigen

(HBsAg),hepatitisCvirusantibody(anti-HCV),anti-Treponemapallidum-

specificantibody(Anti-TP)andanti-humanimmunodeficiencyvirus

antibody(anti-HIV)in22,235casesofpatientsweredeterminedwith

chemiluminescentmicroparticleimmunoassay(CMIA).Thequalitative

detectionofallpositivesampleswerecarriedoutbythecorresponding

enzyme-linkedimmunosorbentassay(ELISA),andtheanti-treponema

pallidumantibody(Anti-TP)positivesampleswereconfirmedby

Treponemapallidumantibodiesgelatinparticleagglutinationtest

(TPPA).ResultsThenumberofpositivecasesofHB-sAg,Anti-HCV,Anti-TP

andAnti-HIVin22,235casesofpatientswere3028,336,684and63

respectively.Thequalitativepositivecasesamongthesepositivesamples

detectedbyELISAwere2472,269,668,and58.603samplesin684casesof

Anti-TPthequantitativepositivesampleswereconfirmedaspositiveby

TPPA.ConclusionCMIAassayforquantificationofpre-transfusioninfection

indicatorscouldbeusedasearlydetectionofinfectionwindowperiodto

reducethemissingrate.Itwouldbeveryhelpfulintheearlydiagnosisand